Wheelock Partners acquired New England Peptide in 2006. During Wheelock’s ownership period, NEP executed a tuck-in acquisition of a competitive division of Sigma Aldrich in 2008.

NEP, founded in 1998, designs and produces custom peptides and polyclonal antibodies for drug, vaccine and diagnostic discovery organizations worldwide. Headquartered in Gardner, Massachusetts, the company’s chemists and immunological experts specialize in delivering a full range of services for biotech and pharmaceutical applications. Peptides are small proteins that play key roles in biochemical regulation of all life systems, helping to fight diseases as diverse as cancer, diabetes, obesity and HIV/AIDS.

Sigma-Genosys, a division of Sigma-Aldrich (NASDAQ:SIAL), sold its custom peptide and polyclonal antibody division to NEP, retaining its other product lines.